- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03846804
Next-Generation Sequencing for Pathogen Detection and Quantification in Children With Musculoskeletal Infections (KDG-002)
Plasma-Based Next-Generation Sequencing for Pathogen Detection and Quantification in Children With Musculoskeletal Infections
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Riley Hospital for Children
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Study Population
Description
Inclusion Criteria:
- 6 months (to ensure adequate blood volume drawn) to 18 years of age.
- Strong clinical suspicion of MSKI as evidenced by fever, osteoarticular pain (e.g. tenderness to palpation of a joint, bone pain, or refusal to bear weight); and elevated ESR (erythrocyte sedimentation rate) or CRP (C-reactive protein).
Exclusion Criteria:
- Subjects will be excluded if they have clinical evidence suggesting an alternative diagnosis; inability or unwillingness to consent for the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Karius Test
Participants will have additional blood drawn for the purposes of analysis with the Karius test.
|
Next-generation sequencing of blood and synovial fluid samples for pathogen identification in children with musculoskeletal infections
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With a Pathogen Identified by the Initial Karius Test (IP1) and Standard Culture Methods
Time Frame: Inpatient Sample 1 (IP1) - Within 48 hours of admission
|
We evaluated the total number of participants that had a pathogen identified by the initial (IP1) Karius Test ("positive Karius Test"). We compared the results of the Karius Test to cultures (gold standard) for each participant. Karius Test results that matched cultures results (same genus and species) were considered "positive agreement". We also evaluated at the number of participants who had negative cultures, but had a positive Karius Test. |
Inpatient Sample 1 (IP1) - Within 48 hours of admission
|
Number of Participants With a Pathogen Identified by the Karius Test (at Time Point IP2) and Standard Culture Methods
Time Frame: Inpatient Sample 2 (IP2) - Within 48 hours of the initial sample
|
We evaluated the total number of participants that had a pathogen identified by the Karius Test ("positive Karius Test") at time point IP2 (within 48 hours of the initial sample). We compared the results of the Karius Test to those with a positive culture (gold standard) for each participant. Karius Test results that matched cultures results (same genus and species) were considered "positive agreement". Karius Test results that identified an organism different from the organism identified in culture were considered "discordant results" Karius Tests results that did not identify any organism were consider "negative" |
Inpatient Sample 2 (IP2) - Within 48 hours of the initial sample
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Microbial Cell Free DNA Level (cfDNA) in Molecules Per Microliter (MPM)
Time Frame: From hospital admission to hospital discharge, up to 3 months
|
We compared the microbial cfDNA level (on initial samples, IP1) between patients with non-severe MSKI to those with severe MSKI (defined as need for intensive care unit (ICU) care; infection in two or more non-contiguous anatomic sites (disseminated disease); need for more than 1 debridement procedure; deep vein thrombosis or thromboembolic disease; or pathologic fracture). Only those with a positive agreement between initial Karius Test (IP1) and culture were analyzed (n=15). Mann-Whitney U was used to compare median microbial cfDNA between those with non-severe vs. severe MSKI. |
From hospital admission to hospital discharge, up to 3 months
|
Microbial Cell Free DNA (cfDNA) in Molecules Per Microliter (MPM) at Time Point IP1
Time Frame: Inpatient Sample 1 (IP1) - Within 48 hours of admission
|
We evaluated whether cfDNA level (in MPM) correlated with C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and white blood cell count (WBC), common inflammatory markers followed in children with MSKI. Spearman's correlation was used to compare the MPM value to the CRP, ESR and WBC |
Inpatient Sample 1 (IP1) - Within 48 hours of admission
|
Microbial Cell Free DNA (cfDNA) in Molecules Per Microliter (MPM) at Time Point IP2
Time Frame: Inpatient Sample 2 (IP2) - Within 48 hours of the admission sample
|
We evaluated whether cfDNA level (in MPM) correlated with C-reactive protein (a common inflammatory marker used to track inflammation in children with MSKI). Spearman's correlation was used to compare the MPM value to the CRP |
Inpatient Sample 2 (IP2) - Within 48 hours of the admission sample
|
Microbial Cell Free DNA (cfDNA) in Molecules Per Microliter (MPM) at Timepoint IP3
Time Frame: Inpatient Sample 3 (IP3) - Within 48 hours of the second inpatient sample
|
We evaluated whether cfDNA level (in MPM) correlated with C-reactive protein (a common inflammatory marker used to track inflammation in children with MSKI) at time point IP3 in participants with positive agreement between the Karius Test and culture. Spearman's correlation was used to compare the MPM value to the CRP |
Inpatient Sample 3 (IP3) - Within 48 hours of the second inpatient sample
|
Microbial Cell Free DNA (cfDNA) in Molecules Per Microliter (MPM) at Time Point IP4
Time Frame: Inpatient Sample 4 (IP4) - Within 48 hours of the third inpatient sample
|
We evaluated whether cfDNA level (in MPM) correlated with C-reactive protein (a common inflammatory marker used to track inflammation in children with MSKI).
|
Inpatient Sample 4 (IP4) - Within 48 hours of the third inpatient sample
|
Microbial Cell Free DNA (cfDNA) in Molecules Per Microliter (MPM) at Time Point OP1
Time Frame: Outpatient Sample 1 (OP1) - 1-2 weeks after hospital discharge
|
We evaluated whether cfDNA level (in MPM) correlated with C-reactive protein (a common inflammatory marker used to track inflammation in children with MSKI).
|
Outpatient Sample 1 (OP1) - 1-2 weeks after hospital discharge
|
Microbial Cell Free DNA (cfDNA) in Molecules Per Microliter (MPM) at Time Point OP2
Time Frame: Outpatient Sample 2 (OP2) - 3-6 weeks after hospital discharge
|
We evaluated whether cfDNA level (in MPM) correlated with C-reactive protein (a common inflammatory marker used to track inflammation in children with MSKI).
|
Outpatient Sample 2 (OP2) - 3-6 weeks after hospital discharge
|
Microbial Cell Free DNA (cfDNA) in Molecules Per Microliter (MPM) at Time Point OP3
Time Frame: Outpatient Sample 3 (OP3) - 6-8 weeks after hospital discharge
|
We evaluated whether cfDNA level (in MPM) correlated with C-reactive protein (a common inflammatory marker used to track inflammation in children with MSKI).
|
Outpatient Sample 3 (OP3) - 6-8 weeks after hospital discharge
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jack G Schneider, MD, Indiana University School of Medicine - Pediatrics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1901296571
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteomyelitis
-
Seattle Children's HospitalMansoura University; Boston Children's Hospital, Boston, MA, USA; Hospital for... and other collaboratorsRecruitingChronic Recurrent Multifocal Osteomyelitis | Chronic Nonbacterial OsteomyelitisUnited States
-
University of LouisvilleOsteo Science FoundationNot yet recruitingOsteomyelitis of JawUnited States
-
Rigshospitalet, DenmarkRecruitingOsteomyelitis; VertebraDenmark
-
Asan Medical CenterCompletedVertebral OsteomyelitisKorea, Republic of
-
Hospices Civils de LyonRecruiting
-
Cubist Pharmaceuticals LLCCompleted
-
Hospices Civils de LyonCompletedOsteomyelitis | Hematogenous Osteomyelitis RelapseFrance
-
Nantes University HospitalCompletedVertebral Osteomyelitis | SpondylodiscitisFrance
-
Assistance Publique - Hôpitaux de ParisCompletedVertebral OsteomyelitisFrance
-
Calvary Hospital, Bronx, NYUnknown
Clinical Trials on Karius Test
-
Karius, Inc.Stanford UniversityCompletedNeutropenia | FeverUnited States
-
Karius, Inc.Duke Clinical Research InstituteCompletedPneumonia, Viral | Pneumonia, Bacterial | Immunocompromised Host | Pneumonia Fungal | Pneumonia CavitaryUnited States
-
Groupe Hospitalier Mutualiste de GrenobleFondation de l'AvenirCompleted
-
Yonsei UniversityCompletedPostprandial Hyperglycemia
-
Recep Tayyip Erdogan University Training and Research...Completed
-
Guven Health GroupCompletedAthletic Performance | Physical Fitness | Handball Players | Cross-sectional StudiesTurkey
-
French National Agency for Research on AIDS and...Completed
-
Clinical Nutrition Research Centre, SingaporeCompleted
-
University of FloridaCompletedParkinson Disease (PD)United States